CSL Hong Kong Biostate Human Coagulation Factor VIII 250IU/von Willebrand factor 500IU complex, Powder for injection (50 IU/mL F

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Von willebrand factor, Quantity: 500 IU; Factor VIII, Quantity: 250 IU

Available from:

CSL Behring Australia Pty Ltd

Pharmaceutical form:

Injection, diluent for

Composition:

Excipient Ingredients: water for injections

Administration route:

Intravenous

Therapeutic indications:

Biostate is indicated for: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von Willebrand disease when desmopressin (DDAVP) treatment is ineffective or contraindicated. - the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.

Product summary:

Visual Identification: Clear, colourless solution free of visible particles; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Authorization status:

Listed (Export Only)

Authorization date:

2001-10-08